Bioethics News

Selecting the Right Tool for the Job

April 16, 2015

(Medical Xpress) – Randomized clinical trials of new drugs have long been considered the “gold standard” in determining safety and efficacy before drugs, biologics, vaccines or devices are introduced to the general public. However, in the case of a deadly, rapidly spreading, infectious disease with no known cure, such as Ebola, ethical considerations demand that reliance only on RCTs be reexamined, according to a new Target Article now online and in print in the American Journal of Bioethics.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.